Meier, Juris J.

Partial pancreatectomy in adult humans does not provoke β-cell regeneration

Menge, B. A., Tannapfel, A., Belyaev, O., Drescher, R., Müller, C., Uhl, W., Schmidt, W. E., & Meier, J. J. (2008) · Diabetes

Pancreatic function and diabetesDiabetes and associated disorders

Cited by 173

Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: A meta-analysis based on cardiovascular outcomes trials

Abd El Aziz, M., Cahyadi, O., Meier, J. J., Schmidt, W. E., & Nauck, M. A. (2020) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacovigilance and Adverse Drug Reactions

Cited by 160

Beta cell mass in diabetes: a realistic therapeutic target?

Meier, J. J. (2008) · Diabetologia

Pancreatic function and diabetesDiabetes and associated disorders

Cited by 155

A meta‐analysis comparing clinical effects of short‐ or long‐acting GLP ‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients

Abd El Aziz, M. S., Kahle, M., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 155

Erythromycin Antagonizes the Deceleration of Gastric Emptying by Glucagon-Like Peptide 1 and Unmasks Its Insulinotropic Effect in Healthy Subjects

Meier, J. J., Kemmeries, G., Holst, J. J., & Nauck, M. A. (2005) · Diabetes

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 146

Efficacy of semaglutide in a subcutaneous and an oral formulation

Meier, J. J. (2021) · Frontiers in Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 146

Postprandial Suppression of Glucagon Secretion Depends on Intact Pulsatile Insulin Secretion

Meier, J. J., Kjems, L. L., Veldhuis, J. D., Lefèbvre, P., & Butler, P. C. (2006) · Diabetes

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 144

Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes

Nauck, M. A., El-Ouaghlidi, A., Gabrys, B., Hücking, K., Holst, J. J., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Meier, J. J. (2004) · Regulatory Peptides

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 137

Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme

Thethi, T. K., Pratley, R., & Meier, J. J. (2020) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 134

Efficacy, safety, and mechanistic insights of cotadutide, a dual receptor glucagon-like peptide-1 and glucagon agonist

Parker, V. E. R., Robertson, D., Wang, T., Hornigold, D. C., Petrone, M., Cooper, A. T., Posch, M. G., Heise, T., Plum-Moerschel, L., Schlichthaar, H., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 123

The glucagon-like peptide-1 metabolite GLP-1-(9–36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans

Meier, J. J., Gethmann, A., Nauck, M. A., Götze, O., Schmitz, F., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Holst, J. J. (2006) · American Journal of Physiology-Endocrinology and Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 104

Risk of pancreatitis in patients treated with incretin-based therapies

Meier, J. J., & Nauck, M. A. (2014) · Diabetologia

Diabetes Treatment and ManagementPancreatitis Pathology and Treatment

Cited by 101

Efficacy and safety of short- and long-acting glucagon-like peptide 1 receptor agonists on a background of basal insulin in type 2 diabetes: a meta-analysis.

Huthmacher, J. A., Meier, J. J., & Nauck, M. A. (2020) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 91

Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes

Meier, J. J., Weyhe, D., Michaely, M., Senkal, M., Zumtobel, V., Nauck, M. A., Holst, J. J., Schmidt, W. E., & Gallwitz, B. (2004) · Critical Care Medicine

Hyperglycemia and glycemic control in critically ill and hospitalized patientsDiabetes Treatment and Management

Cited by 89

The incretin/glucagon system as a target for pharmacotherapy of obesity

Del Prato, S., Gallwitz, B., Holst, J. J., & Meier, J. J. (2022) · Obesity Reviews

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 77

GIP and GLP-1: stepsiblings rather than monozygotic twins within the incretin family

Nauck, M. A., & Meier, J. J. (2019) · Diabetes

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 65

Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes

Quast, D. R., Schenker, N., Menge, B. A., Nauck, M. A., Kapitza, C., & Meier, J. J. (2020) · Diabetes Care

Diabetes Treatment and ManagementGastrointestinal motility and disorders

Cited by 64

Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short‐ and long‐acting glucagon‐like peptide‐1 receptor agonists in type 2 diabetes

Quast, D. R., Nauck, M. A., Schenker, N., Menge, B. A., Kapitza, C., & Meier, J. J. (2021) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 39

GLP-1 receptor agonists in type 1 diabetes: a MAG1C bullet?

Nauck, M. A., & Meier, J. J. (2020) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 24

GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?

Nauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 22

Proinsulin levels in patients with pancreatic diabetes are associated with functional changes in insulin secretion rather than pancreatic β-cell area

Breuer, T. G. K., Menge, B. A., Banasch, M., Uhl, W., Tannapfel, A., Schmidt, W. E., Nauck, M. A., & Meier, J. J. (2010) · European Journal of Endocrinology

Pancreatic function and diabetesPancreatitis Pathology and Treatment

Cited by 20

Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio‐vascular outcome trials

Nauck, M. A., Meier, J. J., & Schmidt, W. E. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPancreatic and Hepatic Oncology Research

Cited by 19

Another milestone in the evolution of GLP-1-based diabetes therapies

Nauck, M. A., Quast, D. R., & Meier, J. J. (2021) · Nature Medicine

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 7